AVBP logo

ArriVent BioPharma (AVBP) Company Overview

Profile

Full Name:

ArriVent BioPharma, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

January 26, 2024

Indexes:

Not included

Description:

ArriVent BioPharma focuses on developing innovative therapies for patients with serious diseases. The company specializes in creating and advancing biopharmaceutical products, aiming to improve treatment options and outcomes in areas with high unmet medical needs. Their commitment is to enhance patient health through cutting-edge research and development.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 22, 25 HC Wainwright & Co.
Buy
Nov 15, 24 HC Wainwright & Co.
Buy
Sep 11, 24 Citigroup
Buy
Sep 10, 24 Oppenheimer
Outperform
Sep 10, 24 HC Wainwright & Co.
Buy
Sep 10, 24 Goldman Sachs
Buy
Aug 16, 24 HC Wainwright & Co.
Buy
Aug 15, 24 Oppenheimer
Outperform
Jun 6, 24 HC Wainwright & Co.
Buy
May 9, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
AVBP
marketbeat.comNovember 6, 2024

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
AVBP
globenewswire.comAugust 12, 2024

First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session

ArriVent Appoints John Hohneker, M.D., to its Board of Directors
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
AVBP
globenewswire.comMay 16, 2024

ArriVent BioPharma, Inc., a company focused on advancing innovative biopharmaceutical therapeutics globally, has appointed John Hohneker, M.D. to its Board of Directors. Dr. Hohneker, who has more than three decades of experience in biopharmaceutical leadership and drug development, currently sits on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., as well as private companies Sonata Therapeutics and Trishula Therapeutics.

ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment
ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment
ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment
AVBP
Seeking AlphaJanuary 29, 2024

ArriVent raised $150 million in an upsized IPO, marking one of the strongest performances for a China-linked IPO in New York over the last two years. The company has licensed global rights, excluding Greater China, to furmonertinib, a highly targeted drug used to treat non-small-cell lung cancer.

FAQ

  • What is the ticker symbol for ArriVent BioPharma?
  • Does ArriVent BioPharma pay dividends?
  • What sector is ArriVent BioPharma in?
  • What industry is ArriVent BioPharma in?
  • What country is ArriVent BioPharma based in?
  • When did ArriVent BioPharma go public?
  • Is ArriVent BioPharma in the S&P 500?
  • Is ArriVent BioPharma in the NASDAQ 100?
  • Is ArriVent BioPharma in the Dow Jones?
  • When was ArriVent BioPharma's last earnings report?
  • When does ArriVent BioPharma report earnings?
  • Should I buy ArriVent BioPharma stock now?

What is the ticker symbol for ArriVent BioPharma?

The ticker symbol for ArriVent BioPharma is NASDAQ:AVBP

Does ArriVent BioPharma pay dividends?

No, ArriVent BioPharma does not pay dividends

What sector is ArriVent BioPharma in?

ArriVent BioPharma is in the Healthcare sector

What industry is ArriVent BioPharma in?

ArriVent BioPharma is in the Biotechnology industry

What country is ArriVent BioPharma based in?

ArriVent BioPharma is headquartered in United States

When did ArriVent BioPharma go public?

ArriVent BioPharma's initial public offering (IPO) was on January 26, 2024

Is ArriVent BioPharma in the S&P 500?

No, ArriVent BioPharma is not included in the S&P 500 index

Is ArriVent BioPharma in the NASDAQ 100?

No, ArriVent BioPharma is not included in the NASDAQ 100 index

Is ArriVent BioPharma in the Dow Jones?

No, ArriVent BioPharma is not included in the Dow Jones index

When was ArriVent BioPharma's last earnings report?

ArriVent BioPharma's most recent earnings report was on Nov 14, 2024

When does ArriVent BioPharma report earnings?

The next expected earnings date for ArriVent BioPharma is Feb 28, 2025

Should I buy ArriVent BioPharma stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions